Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
At Cymbiotika, we believe that any wellness goal should be rooted in high-quality sourcing and superior delivery
How much can tirzepatide reduce liver fat
Giralt S, Estey E, Albitar M, van Besien K, Rondn G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Krbling M, Keating M, Kantarjian H, Champlin R
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
, , , , , , , , , , , ,